To establish incidence and risk factors for development of second malignant neoplasms after high-dose chemo/radiotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT), the case files of 800 consecutive patients who underwent AHSCT at our institution between June 1982 and December 2000 were reviewed. In all, 26 patients developed 29 second malignancies (nine myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML), 16 solid tumors and four lymphoproliferative disorders (LPDs)) for a 15-year cumulative incidence of 11% (95% confidence interval (CI), 5-18%). These second tumors occurred at a median of 68 (range 1.5-177) months following AHSCT. The relative risk (RR) compared to the general population of developing a second malignancy following AHSCT was 3.3 (CI 2.2-4.7) Po0.001. The RR of developing MDS/ AML, LPD and a solid tumor was 47.2 (CI 21.5-89.5) Po0.001, 8.1 (2.2-20.7) P ¼ 0.002 and 1.98 (1.1-3.2) P ¼ 0.009, respectively. In multivariate analysis, age X35 years at the time of AHSCT (P ¼ 0.001) and an interval from diagnosis to AHSCT X36 months (P ¼ 0.03) were associated with a greater risk of developing a second malignancy. Patients who have undergone HDT and AHSCT are at significant risk for developing a second malignancy and should receive indefinite follow-up. Bone Marrow Transplantation (2003) 32, 915-923.
Summary:
To establish incidence and risk factors for development of second malignant neoplasms after high-dose chemo/radiotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT), the case files of 800 consecutive patients who underwent AHSCT at our institution between June 1982 and December 2000 were reviewed. In all, 26 patients developed 29 second malignancies (nine myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML), 16 solid tumors and four lymphoproliferative disorders (LPDs)) for a 15-year cumulative incidence of 11% (95% confidence interval (CI), 5-18%). These second tumors occurred at a median of 68 (range 1.5-177) months following AHSCT. The relative risk (RR) compared to the general population of developing a second malignancy following AHSCT was 3.3 (CI 2.2-4.7) Po0.001. The RR of developing MDS/ AML, LPD and a solid tumor was 47.2 (CI 21.5-89.5) Po0.001, 8.1 (2.2-20.7) P ¼ 0.002 and 1.98 (1.1-3.2) P ¼ 0.009, respectively. In multivariate analysis, age X35 years at the time of AHSCT (P ¼ 0.001) and an interval from diagnosis to AHSCT X36 months (P ¼ 0.03) were associated with a greater risk of developing a second malignancy. Patients who have undergone HDT and AHSCT are at significant risk for developing a second malignancy and should receive indefinite follow-up. Bone Marrow Transplantation (2003) 32, 915-923. doi:10.1038/sj.bmt.1704243 Keywords: high-dose chemo/radiotherapy; autologous stem cell transplantation; second malignancy High-dose chemo/radiotherapy (HDT) and hematopoietic stem cell transplantation (HSCT) have been shown to be an effective therapy for a variety of hematologic and nonhematologic malignancies. [1] [2] [3] [4] [5] However, it has become apparent as more patients survive both their disease and the early post HSCT period that there are potential long-term complications. 6 One complication that understandably raises great concern is the possibility of developing a second (ie new) malignancy following successful treatment of the primary disease.
Patients are known to be at increased risk for EpsteinBarr virus lymphoproliferative disorders (EBV-LPDs) and solid tumors following allogeneic HSCT with a 10-year cumulative incidence of 10-15%. [7] [8] [9] [10] [11] [12] In this patient population, advanced age, male gender, underlying immunodeficiency states, total body irradiation (TBI) conditioning, donor/recipient histoincompatibility, T-cell depletion of bone marrow (BM), the development of graft-versus-host disease and the use of antithymocyte globulin have all been identified as risk factors for second tumors. [7] [8] [9] [10] [11] [12] An increasing number of studies have recently been published establishing the higher incidence of second malignancies following autologous HSCT (AHSCT) compared to the general population and the risk factors leading to their development. 7, [12] [13] [14] [15] [16] [17] [18] [19] [20] This is particularly true of the risk for developing myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) in which both pretransplant chemo/radiotherapy exposure and HDT may be important predisposing factors. [20] [21] [22] [23] It has also been suggested that the HDT may play a direct role in the development of second solid tumors following AHSCT, 24 although much less information has been published on the risk factors for second solid tumor development. In an attempt to establish the incidence of second malignancy and to identify potential risk factors for their occurrence, we retrospectively studied a large cohort of patients who underwent AHSCT at our center over an 18.5-year period.
Patients and methods

Patient characteristics
Between June 1982 and December 2000, 800 patients underwent HDT and AHSCT at the Vancouver General Hospital (VGH), the British Columbia Cancer Agency (BCCA) and British Columbia's Children's Hospital (BCCH). Patient characteristics are shown in Table 1 . All patients (or their legal guardians) provided an informed consent for treatment and all research studies were approved by the University and Institutional Review Boards.
Conditioning regimen
Details of the conditioning regimens are shown in Table 2 ; all doses were based on the lesser of corrected body weight (0.5 (ideal body weight þ actual body weight)) or actual body weight. The HDT regimen utilized was dependent on primary diagnosis and prior exposure to radiotherapy. Standard supportive care techniques were employed as previously described. 4 
Stem cell transplantation
The stem cell source varied over the time period of study, as shown in Table 2 . Patients with a history of prior pelvic irradiation or BM contamination with lymphoma or nonhematopoietic malignant cells, preferentially underwent blood stem cell (BSC) collections. In all other cases, stem cells were collected according to institutional protocol and patient or physician preference. In 255 patients (32%), the stem cells underwent in vitro purging; 76 patients with acute leukemia, 55 patients with non-Hodgkin's lymphoma (NHL), 30 patients with multiple myeloma, two patients with MDS, one patient with Hodgkin's disease (HD) and three patients with solid tumors had their stem cells treated with either 4-hydroperoxycyclophosphamide (4-HC; 124 patients) or mafosfamide (MAF; 43 patients). 25, 26 A total of 41 patients with AML, one patient with acute lymphoblastic leukemia (ALL) and one patient with MDS underwent an interleukin-2 (IL-2)-purged AHSCT 27 and 45 patients with chronic myeloid leukemia (CML) had their BM purged by long-term culture (LTC) as previously reported. 28 
Second malignancy diagnosis
Following AHSCT, patients were routinely monitored in the VGH, BCCA or BCCH Outpatient Clinic and through their referring physicians. Evaluations included, at a minimum, yearly physical examinations and complete blood counts. BM examination was performed as required by the institutional protocol or if unexpected clinical or laboratory changes were noted. All second malignancies were confirmed by central review of the histopathology specimens by an appropriate pathologist at VGH, BCCA or BCCH. In order to be classified as a second malignancy in those patients with primary acute or chronic leukemia, a MDS/ AML had to have a different immunophenotype, FAB subtype or BM karyotype. Nonmelanoma skin cancers were excluded as second malignancies from this analysis.
Statistical analysis
The cumulative probability of developing a second malignancy following AHSCT was determined using the competing risks method of Kalbfleisch and Prentice. 29 The time at risk for the development of a second malignancy was calculated from the date of AHSCT to either the date of death, the date of diagnosis of second neoplasm, the date of last follow-up or to the end of the period of analysis (December 31, 2002) . The following were analyzed as potential risk factors for the development of second malignancy following AHSCT: age (at AHSCT), sex, diagnosis, disease duration, history of prior radiotherapy, HDT regimen (TBI vs non-TBI), stem cell source (BM vs BSC) and purging technique (4-HC/MAF vs IL-2/LTC vs none). Risk factors were evaluated for association with the development of a second cancer by univariate and multivariate analysis utilizing a Cox proportional-hazards regression model. 30 The same risk Second malignancy post auto stem cell transplant factors (excluding stem cell source) were evaluated for association with the development of solid tumors. To determine whether the patients studied were at increased risk of developing a second malignancy, comparisons were made with the age-and gender-specific population data collected by the British Columbia (BC) Cancer Registry. The relative risk (RR) was calculated by comparing second malignancy rates observed in the study cohort with the rates that would be expected based on the Registry data. For patients developing more than one post AHSCT malignancy, the first of these second cancers was used in the risk factor analysis and calculation of the cumulative probability of second malignancy. The overall survival for patients developing a second malignancy was calculated using the methods of Kaplan and Meier. 31 
Results
Transplantation outcome
There are currently 351 patients who are alive and well, with the estimated 15-year event-free survival being 28% (95% confidence interval (CI) 23-34%). In all, 376 patients have experienced a relapse of their primary malignancy, and 133 patients died of complications related to their AHSCT; one patient died in a motor vehicle accident while in remission 4.3 years post AHSCT. Actuarial risk of relapse and nonrelapse mortality was 51% (CI 46-56%) and 21% (CI 16-27%), respectively.
Second malignancies
In 
Treatment-related MDS/AML
Nine of the 29 second neoplasms were hematopoietic, six MDS and three AML ( Table 3 
Solid tumors
In total, 15 patients developed 16 solid tumors (GI (3), lung (3), CNS (2), GU (2), liver (2), bone (2), breast (1), oral cavity (1)) a median of 74 (range 17-160) months post AHSCT ( Second malignancy post auto stem cell transplant
Lymphoproliferative disorders
Four patients developed post transplant LPDs (Table 5) . Two patients (UPN 632, 1272) had undergone AHSCT for relapsed HD and developed NHL 70 and 66 months post AHSCT, respectively. Both patients remain alive and well after receiving multiagent chemotherapy. Two patients (UPN 857 and 1501) developed EBV-LPD, both of which have been the subject of previous reports. 33, 34 UPN 857 had received an LTC-purged AHSCT for CML in first stable phase. Following engraftment, he developed a post transplant B-cell LPD and he was commenced on acyclovir, corticosteroids, intravenous immunoglobulin and alpha-interferon. The EBV-LPD regressed, but 79 months post AHSCT he developed squamous cell carcinoma of the tongue and died of metastatic carcinoma. UPN 1501 underwent a renal transplant for IgA nephropathy 9 years before undergoing AHSCT for an EBV-negative, lambda light-chainrestricted small noncleaved cell NHL. At 1.5 months post AHSCT, she began circulating abnormal lymphocytes and developed hepatic dysfunction. Liver biopsy showed infiltration with a kappa light-chain-restricted EBV-positive LPD. No therapy was instituted and the patient died 5 days later.
Probability of second cancer
At the time of the analysis, the study cohort had accumulated a follow-up of 2990 patient-years with the median follow-up for surviving patients being 63 months. The cumulative risk of developing any second malignancy at 15 years was 11% (CI 5-18%) (Figure 2 
Risk factors for second cancer
In univariate analysis, age at time of AHSCT (P ¼ 0.002) and disease duration (P ¼ 0.002) were significant risk factors for the development of a second malignancy (Table 6 ). These two factors remained significant in multivariate analysis with P ¼ 0.001 and 0.034, respectively ( Table 6 ). The 15-year actuarial probabilities for developing a second malignancy in patients o35 and X35 years of age at the time of AHSCT were 5% (CI 1-12%) and 17% (CI 7-31%), respectively (P ¼ 0.001) (Figure 3 ). The 15-year actuarial probabilities for developing a second malignancy in patients whose interval from diagnosis to AHSCT was o36 or X36 months were 6% (CI 3-12%) and 23% (CI 8-43%), respectively (P ¼ 0.03) (Figure 4 ). When the analysis was restricted to second solid tumors, none of the risk factors examined were significant in univariate or multivariate analysis.
Discussion
In this study of 800 patients who received an AHSCT at our institution, 29 second neoplasms occurred in 26 Second malignancy post auto stem cell transplant DL Forrest et al patients, resulting in a cumulative risk of developing a second malignancy of 11% at 15 years. This corresponded to a RR of 3.3 compared to the general population when adjusted for age and gender. Similar to previous reports, [11] [12] [13] [15] [16] [17] [18] tMDS/AML accounted for many of the second cancers in our study population and except for one case, all occurred within 10 years of AHSCT. This is in keeping with the known shorter latency period of tMDS/ AML as compared to solid tumors. It is worth noting that three of the nine patients developing tMDS/AML had a diagnosis of AML prior to HSCT. While it is possible that the tMDS/AML could simply represent a relapse of the original leukemic clone, we felt that a therapy-induced malignancy was more likely. Marked BM dysplasia, which had not been a feature at diagnosis, along with new karyotypic abnormalities uncommonly seen in de novo AML (À7, t(1;6)), provides support for this contention.
In our patient cohort, 16 solid tumors were observed in 15 patients during the 18.5-year follow-up period with an RR of 1.98, P ¼ 0.009 when compared to the age-and yrs, years; HD, Hodgkin's disease; NHL, non-Hodgkin's lymphoma; MM, multiple myeloma; mos, months; HDCT, high-dose chemo/radiotherapy; TBI, total body irradiation; 4-HC, 4-hydroperoxycyclophosphamide; MAF, mafosfamide; IL-2, interleukin-2; LTC, long-term culture. gender-specific population data. Two of these neoplasms were hepatocellular carcinomas, but both originated in patients known to have chronic hepatitis C, a well-known etiologic factor. 35 Two patients developed brain tumors, both of whom had previously been treated with mantle radiotherapy. Of the 16 solid tumors, five occurred within previous irradiation fields or in patients who received TBIbased conditioning regimens. The total number of second solid tumors developing in our study cohort is similar to that previously reported in the literature. Among 750 patients undergoing AHSCT at the University of Minnesota, seven patients developed second solid tumors. 12 Similarly, a French study reported 8 second tumors developing among 467 patients undergoing AHSCT for HD with a cumulative incidence of second cancers following AHSCT of 8.9%. 24 No risk factors for the development of solid tumors post AHSCT was found in either of these two studies, although there was a trend for an increased incidence of second solid tumors for those patients receiving TBI-based conditioning regimens in the report from Minnesota, but this did not reach statistical significance. 12 Similarly, we did not identify any risk factors for the development of second solid tumors in our post AHSCT recipients. It would be anticipated, however, that more solid tumors will develop as the follow-up period increases in our patient cohort, reflecting the longer latency period known for solid tumor development. 36 In this study, two patients transplanted for relapsed HD developed post AHSCT NHL. The development of NHL after chemo/radiotherapy for HD has been well described in previous reports. 13, 37 In addition, there were two cases of post AHSCT EBV-LPD. The occurrence of EBV-LPD post AHSCT is unusual and it has been more commonly reported in association with solid organ transplant recipients and in the setting of intense immunosuppression post allogeneic HSCT. 38 One of two patients developing EBV-LPD in this report had undergone a renal transplant prior to AHSCT. It is possible that the additional immunosuppression related to the solid organ transplant in this particular case contributed to an increased risk for developing an EBV-LPD post AHSCT.
A number of potential risk factors for the development of second malignancies following AHSCT have been previously described. The use of TBI conditioning regimens, advanced patient age, prior radiotherapy exposure, in vitro purging of the stem cells and the use of BSC rather than BM have all been linked to an increased risk of second malignancy. 12, 13, 15, [17] [18] [19] The infusion of a low mononuclear cell dose has also been correlated to the development of tMDS/AML. 39, 40 Prior fludarabine therapy may also predispose to tMDS/AML following AHSCT, 40 a concern that has previously been raised with regard to purine analogues. 41 The Socie´te´Franc¸aise de Greffe de Moelle study found that age at the time of AHSCT was a critical risk factor for the development of a second malignancy as was the use of BSC rather than BM as a stem cell source. 24 The explanation for the latter finding is uncertain, but it has been suggested that immunoreconstitution may be more impaired after BSC or that the use of certain priming agents and/or hematopoietic growth factors to collect BSC may promote evolution of an abnormal clone. 42 In our study, four of the 26 patients developing a second malignancy received BSC. We did not find an increased incidence of second tumors in this cohort as compared to patients receiving BM, although the follow-up period for the BSC group is understandably shorter. However, we did find that age at the time of AHSCT had a significant effect on probability of developing a second tumor, with a cumulative probability of 17% at 15 years in those patients X35 years of age vs 5% in patients o35 years. Since the incidence of cancer in the general population increases with age, this finding is not surprising. However, the increase in the age-adjusted RR suggests that the risk of a new malignancy is higher even when advanced age is accounted for. This is consistent with the multistep hypothesis of leukemo-carcinogenesis; it is conceivable that a critical step in the process is the impairment of DNA repair that occurs with aging. 43 There remains substantial controversy as to the importance of the HDT in the development of a second tumor. It is known that patients exposed to chemotherapy (particularly alkylating agents and epidophyllotoxins) are at increased risk of developing tMDS/AML. 19, 37, [44] [45] [46] It is also evident that exposure to ionizing radiation increases the incidence of both acute leukemia and solid tumors. 36, 47, 48 Furthermore, a genetic predisposition to malignancy has been described in several disorders. 49 In our study, a longer interval from diagnosis to AHSCT was associated with a greater risk of developing a second cancer post transplant. This observation has been previously reported in the literature. 17, 20, 40 Unfortunately, we did not have comprehensive records of pretransplant chemotherapy administered and therefore we could not specifically examine the effect of initial chemotherapy on the risk of developing a second cancer post AHSCT. However, we did not find an increased incidence of second cancers among the patients who had received radiotherapy prior to AHSCT. In one study however, nine of 12 patients developing tMDS post AHSCT had identical cytogenetic abnormalities in both their pre-HDT stem cell specimens and their BM showing tMDS, suggesting that in many cases prior therapy is responsible. 23 This contention is further supported by a recent study from Sobecks et al, 22 who have reported six cases of tMDS/AML in 649 patients post AHSCT with a median latency period of 5.5 years from diagnosis of the primary malignancy and only 1.5 years from HSCT. The typical latency period between conventional therapy administration and tMDS/AML in HD and NHL is also in the order of 5 years. 44, 45 The fact that the time elapsed from conventional chemotherapy is similar in both situations suggests that the development of the second malignancy is not due to the HDT. This conclusion is in contrast, however, to the experience from both the Dana-Farber Cancer Institute and St Bartholomew's Hospital which report a median latency period of 4 years from AHSCT to tMDS/AML, consistent with a role for the HDT (cyclophosphamide/TBI in all patients in the studies) in the pathogenesis of the second malignancy. 39, 40 Previous reports have addressed the issue of new clonal cytogenetic abnormalities following AHSCT and their possible relationship to stem cell purging. 15, 50, 51 van den Akker et al 50 found that two of 13 patients with tAML had developed secondary clonal abnormalities involving chromosome 1 (only infrequently reported in de novo AML), following in vitro stem cell purging with a cyclophosphamide derivative. This result was confirmed in a larger study by Perot et al, 51 who also described a high incidence of new cytogenetic abnormalities after MAF-purged AHSCT. Of interest, two of the patients in our study who developed tMDS following 4-HC-purged AHSCT had karyotypic abnormalities involving chromosome 1. However, it is not clear whether the conditioning regimen or the purging process was primarily responsible for the development of the new abnormalities. Genetic marking of the infused stem cells could identify the source of the malignant clone in this situation. 52 The prognosis for AHSCT recipients with acquired clonal cytogenetic abnormalities may not necessarily be poor provided there is no increase in blast cell percentage and no evidence of morphologic dysplasia. 16 However, the prognosis for patients who develop a solid tumor, highgrade tMDS or tAML after AHSCT is poor. 12, [16] [17] [18] Even the use of an allogeneic HSCT has not been a successful strategy for patients with tMDS/AML following a prior AHSCT. 39 None of the nine patients with tMDS/AML in our study and only five of the 19 patients with second solid tumors or LPD are alive. Close clinical follow-up for survivors of AHSCT is warranted to hopefully enable early detection of second malignancies.
This study has evaluated a heterogeneous population of patients undergoing AHSCT for a variety of malignant diseases. The variable pretransplant factors, conditioning regimens, etc make it difficult to predict the risk of second malignancy for individual patients. However, the findings of this study indicate that AHSCT recipients, particularly those X35 years of age and those whose interval from diagnosis to AHSCT is X36 months, are at an increased risk of developing a second malignancy after HDT. The latency period for second tumors in this situation may be long, and extended follow-up will be needed to precisely define their incidence and to examine more fully potential risk factors.
